This paper is only available as a PDF. To read, Please Download here.
A multicenter, parallel-group, double-blind, randomized, outpatient study compared the efficacy and safety of etodolac versus naproxen in patients with osteoarthritis of the knee. After a washout period free of nonsteroidal anti-inflammatory drugs, 254 patients self-administration etodolac 400 mg (n = 86), naproxen 500 mg (n = 82), or placebo (n = 86) twice daily for 4 weeks. Compliance exceeded 90% in all three groups. Primary efficacy variables improved progressively from baseline in all three groups. The extent of improvement was greater in the etodolac and naproxen groups than in the placebo group (P ≤ 0.003), except with respect to target joint tenderness (P = 0.028, etodolac vs placebo; P = 0.013, naproxen vs placebo). There were no statistical differences between active treatment groups (P > 0.1). At end point, twice as many patients responded in the etodolac (59%) and naproxen groups (51%) than in the placebo group (26%; P ≤ 0.01). There were no significant between-group differences in the numbers of patients who had an adverse experience, a serious adverse experience, or an adverse experience leading to study discontinuation; there were also no significant between-group differences in the distribution of adverse experiences. There were no unexpected clinical or laboratory experiences. Etodolac 400 mg twice daily was as effective and safe as naproxen 500 mg twice daily and both were superior to placebo in the management of osteoarthritis of the knee.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Osteoarthritis.in: DiPiro JT Talbert RL Hayes PE 2nd ed. Pharmacotherapy. A Pathophysiologic Approach. Appleton & Lange, Norwalk, Conn1993: 1330-1342
- Osteoarthritis.in: Wilson JD Braunwald E Isselbacher KJ 12th ed. Harrison's Principles of Internal Medicine. McGraw-Hill, New York1991: 1475-1479
- Naproxen efficacy—a reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.Drugs. 1990; 40: 91-137
- A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis.Br J Clin Pract. 1994; 48: 67-69
- Double-blind, parallel comparison of etodolac and naproxen in patients with osteoarthritis of the knee.Acta Ther. 1991; 17: 19-34
- Double-blind comparison of etodolac and naproxen in patients with osteoarthritis.Acta Ther. 1991; 17: 5-18
- a49th ed. Physicians' Desk Reference®. Medical Economics Data Production Company, Montvale, NJ1995: 2478-2480
- b49th ed. Physicians' Desk Reference®. Medical Economics Data Production Company, Montvale, NJ1995: 2682-2685
- Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs.Agents Actions. 1982; 12: 295-297
- An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa.J Rheumatol. 1987; 14: 338-341
- Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy.Br J Rheumatol. 1989; 28: 329-332
- Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.Ann Rheum Dis. 1990; 49: 354-358
- Double-blind parallel comparison of etodolac and diclofenac S.R. in patients with osteoarthritis of the knee.Acta Ther. 1991; 17: 345-354
- Double-blind, parallel-group evaluation of the safety and efficacy of etodolac compared with diclofenac in patients with osteoarthritis of the knee.Acta Ther. 1993; 19: 137-150
- Comparison of etodolac and diclofenac in osteoarthritis of the knee.Clin Ther. 1992; 14: 791-800
- Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee.Curr Med Res Opin. 1991; 12: 309-317
- A double-blind comparison of etodolac and piroxican in the treatment of osteoarthritis.Curr Med Res Opin. 1990; 12: 255-262
- Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee.Curr Med Res Opin. 1991; 12: 401-412
- Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee.Clin Ther. 1995; 17: 602-612
- Strategies for preventing NSAID-induced ulcers.Drug Therapy. 1994; 24: 25-32
- Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects.Curr Ther Res. 1985; 37: 730-738
- Results of a four-week, prospective, randomized, double-blind comparison of placebo, Lodine Rx, and naproxen in healthy volunteers.Presented at Digestive Disease Week. 14171994; (New Orleans, Louisiana)
- Worldwide experience with etodolac (Lodine®) 300 mg b.i.d. in the treatment of osteoarthritis.Rheumatol Int. 1993; 13 (Suppl): S7-S12
© 1995 Published by Elsevier Inc.